Literature DB >> 21922144

Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3.

Yukio Fujiwara1, Yoshihiro Komohara, Rino Kudo, Keiichiro Tsurushima, Koji Ohnishi, Tsuyoshi Ikeda, Motohiro Takeya.   

Abstract

Tumor-associated macrophages (TAMs) polarized to the M2 phenotype promote tumor cell proliferation and are associated with a poor prognosis in patients with high grade glioma. We previously revealed that corosolic acid, a triterpenoid compound, inhibits the M2 polarization of human monocyte-derived macrophages (HMDM). In the present study, we examined whether oleanolic acid (OA), a triterpenoid compound whose structure is similar to corosolic acid, also shows inhibitory effects on M2 polarization in HMDM. OA significantly inhibited the expression of CD163, one of the phenotype markers of M2 macrophages, as well as suppressed the secretion of IL-10, one of the anti-inflammatory cytokines preferentially produced by M2 macrophages, thus suggesting that OA suppresses the M2 polarization of macrophages. Furthermore, OA inhibited the proliferation of U373 human glioblastoma cells, and the activation of signal transducer and activator of transcription-3 (STAT3) in both human macrophages and glioblastoma cells. These results indicate that OA suppresses the M2 polarization of macrophages and tumor cell proliferation by inhibiting STAT3 activation. Therefore, OA may be a potentially new agent that can be used for the prevention and treatment of various malignant tumors, including glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922144     DOI: 10.3892/or.2011.1454

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  35 in total

1.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

2.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

Review 3.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

4.  Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.

Authors:  Xuechao Li; Yarong Song; Peng Zhang; Hongxue Zhu; Lifeng Chen; Yajun Xiao; Yifei Xing
Journal:  Tumour Biol       Date:  2015-12-18

Review 5.  Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Authors:  Sylvia C Kurz; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2018-04-18       Impact factor: 3.598

Review 6.  The role of STAT3 in tumor-mediated immune suppression.

Authors:  Sherise D Ferguson; Visish M Srinivasan; Amy B Heimberger
Journal:  J Neurooncol       Date:  2015-02-22       Impact factor: 4.130

Review 7.  Anti-tumour strategies aiming to target tumour-associated macrophages.

Authors:  Xiaoqiang Tang; Chunfen Mo; Yongsheng Wang; Dandan Wei; Hengyi Xiao
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

8.  Liposome Delivery of Natural STAT3 Inhibitors for the Treatment of Cancer.

Authors:  Max Kullberg; Alexandra Francian; Ameneh Arabi; Troy Olsson; Kristine Mann; Holly A Martinson
Journal:  Pharm Front       Date:  2019-11-28

Review 9.  STAT3 activation: A key factor in tumor immunoescape.

Authors:  Cédric Rébé; Frédérique Végran; Hélène Berger; François Ghiringhelli
Journal:  JAKSTAT       Date:  2013-01-01

Review 10.  The immune landscape of common CNS malignancies: implications for immunotherapy.

Authors:  Martina Ott; Robert M Prins; Amy B Heimberger
Journal:  Nat Rev Clin Oncol       Date:  2021-06-11       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.